Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is a fertility benefits management company that offers a wide range of fertility and family building benefits solutions to clients across various industries. The company has a strong track record of client retention and has been able to maintain a high level of revenue growth through expansion into new products and services. Additionally, Progyny is well-positioned to continue gaining market share and expanding internationally, making it a promising investment opportunity with strong fundamentals and a positive outlook for the future.

Bears say

Progyny is experiencing declining overall revenue per ART cycle, a potential red flag as it suggests declining demand or increased competition in the fertility market. Additionally, the company's newer offerings are currently included in medical revenue, which can potentially distort the medical revenue per ART cycle calculation. Furthermore, while the company reports strong financials, its stock faces potential volatility due to investor concerns about the impact of unemployment on client retention and sales.

Progyny (PGNY) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 10 analysts, Progyny (PGNY) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.